Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• C. Albany, N.H. Hanna, J. Picus, R.J. Hauke, C.A. Fausel, Z. Liu, M.J. Brames, L.H. Einhorn. Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4594). See abstract.
• Brames MJ, Case-Eads S, Hanna NH, Fausel CA, Breen T, Einhorn LH. Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted as an electronic publication at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr e20737). See abstract.
• Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted for poster presentation at the MASCC/ ISOO Annual Meeting on Supportive Care in Cancer, June 25-27, 2015, Copenhagen Denmark. See abstract.
• Adra N, Albany C, Brames MJ, et al. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study [published online ahead of print February 2, 2016]. Supp Care Cancer. doi:10.1007/s00520-016-3100-y